Packaged Foods and Meats

H&H INTL HLDG

H&amp;amp;H International Reports Q1 2026 Revenue Growth of 33.8% to 4.26 Billion Yuan

H&H International Holdings reports 34.4% revenue growth to 4.3 billion yuan in Q1 2026, debt reduced

CLSA Maintains Buy Rating on H&H International Holdings

H&H International Holdings released FY2025 9 Months Earnings on March 24 (BJT), actual revenue HKD 11.61 B, actual EPS HKD 0.2256

H&H INTL HLDG released FY2025 Q3 earnings on March 24 (BJT), actual revenue HKD 4.009 B, actual EPS HKD 0.1065

H&H International Reports 10% Revenue Growth in FY2025 and Proposes Final Dividend

H&H INTL HLDG released FY2025 Q4 earnings on March 24 Pre-Market (BJT), actual revenue HKD 4.078 B, actual EPS HKD 0.1084

H&H INTL HLDG released FY2025 Annual Earnings on March 24 Pre-Market (BJT), actual revenue HKD 15.69 B (forecast HKD 15.78 B), actual EPS HKD 0.334 (forecast HKD 0.9804)

H&H INTL HLDG to release FY2025 earnings on March 24 Pre-Market (BJT), forecast revenue HKD 16.05 B, EPS HKD 1.002

H&amp;H International Holdings Announces Q1-Q3 Revenue and Growth Projections

CICC Raises Profit Forecast and Target Price for H&amp;H International Holdings

H&H INTL HLDG released FY2025 Q1 earnings on August 26 (BJT), actual revenue HKD 3.759 B, actual EPS HKD 0.0589

H&amp;H International Holdings Announces Mid-Year Results: Revenue Growth, Profit Decline

H&H INTL HLDG released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue HKD 3.841 B, actual EPS HKD 0.0601

H&H INTL HLDG released FY2025 Semi-Annual Earnings on August 26 Pre-Market (BJT), Actual Revenue: HKD 7.6 B, Actual EPS: HKD 0.1191

H&H INTL HLDG to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

H&amp;H International Holding's ESG Rating Dropped to BBB

CLSA downgrades H&amp;H International Holdings' 2025 net profit forecast

H&amp;H International Holdings Sees Mid-Year Profit Drop 45% to 65%

H&amp;H International Holdings Reports Growth in All Business Segments for First Half of 2025

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

H&H International Holdings (1112.HK) 2025 Interim Results Release Conference

01112

H+H International reported a Q1 2026 loss of DKK 47 million on revenue of DKK 560 million, deepening from a loss of DKK 24 million in Q4 2025. The trailing 12-month loss widened to DKK 697 million, raising concerns about profitability despite forecasts of 132.44% earnings growth in the coming years. The stock trades at a low P/S of 0.6x, with a DCF fair value of DKK 389.62, indicating a significant valuation gap. Investors are focused on the potential for margin improvement and sustainable profitability amidst ongoing losses.

Simplywall

H+H International Q1 Loss Deepening To DKK 47 Million Tests Bullish Profitability Narratives

China Merchants Securities has reaffirmed a Buy rating on Health and Happiness (H&H) International Holdings (BTSDF), setting a price target of HK$21.00. The stock closed at HK$14.00 last Friday. The overall analyst consensus for H&H International Holdings is a Strong Buy, with an average price target of HK$18.48.

Tip Ranks

CMSC

China Merchants Securities Keeps Their Buy Rating on Health and Happiness (H&H) International Holdings (BTSDF)

Health and Happiness (H&H) International Holdings reported a 34.4% year-on-year revenue increase in Q1 2026, reaching RMB4.26 billion, driven by strong demand for nutritional supplements, particularly in China. The Baby Nutrition and Care segment saw a 60.9% rise, with infant formula sales surging 74.4%. The company also reduced gross debt by over RMB300 million, enhancing its financial flexibility. Analysts rate the stock as a Buy with a target price of HK$15.80.

H&H Delivers Strong Q1 Revenue Growth on China-Driven Nutrition Demand and Deleveraging

In a report released yesterday, from CLSA maintained a Buy rating on Health and Happiness (H&H) International Holdings, with a price target of HK$16.40. The company’s shares closed last Friday at HK$13.51.Claim 30% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Health and Happiness (H&H) International Holdings has an analyst consensus of Strong Buy, with a price target consensus of HK$17.31.

CLSA Reaffirms Their Buy Rating on Health and Happiness (H&H) International Holdings (BTSDF)

H+H International A/S has been notified that Solbet Sp. Z o.o. has applied to the Polish competition authority for approval to acquire control of H+H. The application was submitted by Solbet, not H+H, and no decision on a takeover offer has been made yet. Solbet intends to proceed only after gaining clarity on the antitrust clearance process, which may take considerable time.

prnewswire

02:30 ETH+H International A/S: Notification to the Polish Competition Authority by Solbet Sp. Z o.o.

Health and Happiness (H&H) International (OTCMKTS:BTSDF) shares rose 1.9% to $1.60, with 100 shares traded. The stock's 50-day and 200-day moving averages are $1.59 and $1.61, respectively. The company specializes in infant nutrition and maternal health products, operating in various Asia-Pacific markets. Analysts currently rate the stock as a Hold, suggesting it may not be a top buy compared to other recommended stocks.

Market Beat

Health and Happiness (H&H) International (OTCMKTS:BTSDF) Shares Up 1.9%  - Should You Buy?

159837

159859

159102

Biostime, the leading brand in children's probiotic and prebiotic supplements, has launched the A-L-G Care™ collection. This new line includes Biostime Baby & Kids Dual Defense and Skin Defense powders, formulated with clinically studied probiotic strains to enhance immunity, skin health, and respiratory wellness in children. Each product is designed to support gut health and is free from artificial additives. The collection aims to help children manage seasonal sensitivities and promote overall health, backed by over 20 years of research.

E Fund CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

ICBCCS SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

11:05 ETBiostime's New A-L-G Care™ Collection of Probiotic-enriched Supplements for Babies and Kids are Formulated with Clinically Studied Probiotic Strains Trusted by Scientific Experts to Help Strengthen Immunity, Support Skin Health, and Promote Nasal & Respiratory Wellness in Babies and Kids*

159843

515170

515710

159736

H&H International announced its 2025 annual performance, with revenue of 14.354 billion RMB (the same below), an increase of 10% year-on-year. It turned a profit of 196 million RMB, compared to a loss of 53.72 million RMB in the same period of 2024; earnings per share were 31 cents. A final dividend of 16 Hong Kong cents was declared, compared to 5 Hong Kong cents in the same period last year. The overall gross profit margin for the period was 62.4%, an increase of 1.8 percentage points year-on-year

AASTOCKS

China Merchants Guozheng Food and Beverage ETF

ChinaAMC CSI Food & Beverage Sub-Industry ETF

Hwabao WP CSI Food & Beverage Sub-Industry ETF

Tianhong CSI Food and Beverage ETF

"Performance" H&H International turned a profit of 196 million RMB for the whole year, with the final dividend increasing to 16 Hong Kong cents

H&H INTL HLDG(01112.HK)